BIOTECH IN BAVARIA TRANSFORMATION IN PROGRESS REPORT 2018/19 including more than 300 company managed by profiles and contact details Future X Healthcare e digital (r)evolution – a new era for patients 14 November 2019 | Munich www.fxh2019.com accelerating biomedical innovation BioM – central point of contact for pharma and biotechnology in Munich and Bavaria ❚ consulting for founders-to-be, ❚ representing Bavarian biotechnology start-ups & SMEs world-wide ❚ grant & seed fi nancing support ❚ investment opportunities ❚ pre-seed incubation & m4 award ❚ central online platform: ❚ matchmaking, networking & partnering job exchange, company database ❚ events, conferences & training and much more www.bio-m.org Bavarian Ministry ofBavarian Ministry of Economic Aairs, Economic Aairs, Regional DevelopmentRegional Development and Energy and Energy Never stop exploring. Be part of the digital future. Right this way for R&D Bavaria is the leading biotech and pharma location in Germany. With a high number of international pharma companies and new rising biotech stars, Bavaria offers the right environment and infrastructure for your company – especially when it comes to R&D. In Bavaria you’ll find the right ingredients: a wealth of potential partners and customers throughout the entire industry value chain and highly qualified personnel. Bavaria is the home of digital future and your perfect business location. Discover the benefits of expanding your business to Bavaria. We do everything to get your business started: From arranging contacts with relevant players to identifying the perfect location for your company. Our service is confidential and free of charge. Get in touch with us! • www.invest-in-bavaria.com IB-Bio-Tech-AZ-A4-2019.indd 1 19.02.19 16:19 CONTENT Greeting 5 Hubert Aiwanger, Bavarian State Minister of Economic Affairs, Regional Development and Energy Preface - Biotechnology in Transformation 7 Prof. Horst Domdey – Spokesman Bavarian Biotechnology Cluster Company Development 8 Stable and growing FCF Life Science Monitor 2018 Advertorial 18 Dr. Mathias Schott and Sebastian Sommer Scientific Landscape 20 Outstanding Research in Bavaria About this Study: DigiMed Bayern 26 For the Bavarian Biotech Report, a biotechnology company Digitization Lighthouse Project in Bavaria has been defined as a company which develops and/ or manufactures products on the basis of state-of-the- art molecular biological methods. Since conventional pharmaceutical companies are also increasingly using such methods, it is often difficult to differentiate between BioM for BioEntrepreneurs 29 biotech and pharma. Guiding you from Idea to Success The biotechnology companies were classified according to the location of the headquarter as ‘international’ or ‘native Bavarian’. The classification into OECD and non-OECD biotech companies as found in previous reports has been International Affairs 30 dispensed with, as this does not accurately portray the Bavaria going global diversity of the biotech pharma ecosystem. Part of the data were collected in cooperation with Bio- Deutschland e.V. It was possible to achieve a response rate to the survey of more than 50%. Possible deviations from Innovation Centers in Bavaria 32 previously published figures are the result of additional Regional Networks in Life Sciences data gathered in this survey that also may refer to previous years. The period under review for this report is 2018. There are about 300 company profiles listed in the appendix of this brochure (pp. 37). Not every company 20 Years of BioPark Regensburg Advertorial 35 listed is also considered in this survey, for example some Dr. Thomas Diefenthal – CEO of BioPark Regensburg GmbH companies with very specific services, or selected medical engineering companies. Furthermore, some Bavarian biotech and pharma companies are included in the survey but have not activated their listing in the database of BioM. M Also more than 500 Bavarian companies in medical Bio - Your Gateway to the Bavarian Biotech Community 36 engineering are not included in this survey. Published in April, 2019 Company Profiles 37 Biotech in Bavaria - Report 2018/19 3 BIOLOGISCHE MECHANISMEN ENTSCHLÜSSELN UND PATIENTEN HELFEN Wir bei Amgen wollen mit den Möglichkeiten der Biotechnologie innovative Therapien und Lösungen für Patienten mit schweren Erkrankungen schaffen. Um neue Therapieansätze zu finden, nehmen wir die komplexen molekularen Mechanismen einer Erkrankung ins Visier. Unser Ziel ist es, nicht nur zur Linderung einer Erkrankung beizutragen, sondern auch die Lebensqualität von Patienten zu verbessern. Weitere Informationen über Amgen finden Sie unter: www.amgen.de © Amgen GmbH 2018. Alle Rechte vorbehalten. RZ_Amgen_AZ_Deutsch_A4_181009.indd 1 09.10.18 16:02 Greeting Hubert Aiwanger GREETING Bavarian State Minister of Economic Affairs Discussions of the opportunities and various interests can be reconciled in risks have been a constant companion the best way possible through dialogue. to biotechnology since it first emerged Innovation and responsibility are not in the 1990s – also in Bavaria. The mutually exclusive in the Free State of debates concerning the value of medical Bavaria. progress alone are a good example. On the one hand, people are understandably More than 20 years ago, the Bavarian State very open to new possibilities when Government set up this innovation space they themselves are affected by HUBERT AIWANGER for biotechnology. The unmistakable illness. Making immediate use of Bavarian State Minister of Economic Affairs, achievements demonstrate that it was innovative technology that promises a Regional Development and Energy the right approach. In drug development, cure should then be possible. On the there are many solutions in Bavaria that other hand, the social discourse with have made the leap from laboratory respect to preimplantation diagnostics, to real life. With respect to industrial for example, clearly indicates the high level of ethical biotechnology, the Free State is also home to globally responsibility that is associated with new procedures. renowned centers where, almost daily, new opportunities In such a case, people expect the various interests to be are created thanks to experimental development. The deliberated thoroughly. dynamic nature of the industry in Bavaria is very special, particularly when compared on an international scale. The task and the challenge from a political perspective is The interplay of medium-sized enterprises and large to find the right balance in this complex scenario. Firstly, corporations is especially impressive. The large biotech a framework must be established in which to facilitate companies have only achieved so much due to the progress technologically. Secondly, the ethical demands of impressive efforts of the Bavarian SMEs in enabling society must be met politically. In this regard, the Bavarian technologies. State Government is pursuing a very clear, long-term The Bavarian biotech industry has an excellent standing goal: to further integrate biotechnology into the Bavarian and, as a location, Bavaria is attractive to companies landscape. We therefore support innovation spaces from around the globe. I wish everyone in the Bavarian where disruptive innovations can grow and flourish. We biotech sector continued success with their ventures into invite stakeholders from business, science and society the ‘real world’ and will be glad to continue supporting alike to become involved in this process so that the them in the future. Hubert Aiwanger Biotech in Bavaria - Report 2018/19 5 VISION AHEAD? BayPAT We help you to achieve your vision by linking the value of intellectual property to company performance. As one of the largest tech transfer offi ces in Europe, we protect and commercialize innovati ons from 33 research insti tutes. WWW.BAYPAT.DE Preface Prof. Horst Domdey BIOTECH IN BAVARIA Biotechnology in Transformation Dear Reader, or ‘Tools for Life Sciences’, as we call this Although biotechnological procedures special interest group (see p. 16). Many such as brewing beer or making of these companies operate globally, and wine, cheese and bread have existed some are even leaders in their field. To for thousands of years, the term achieve this, they have had to adapt biotechnology does not seem to have rapidly to the expectations of their been used until 1919, when the director customers and must continue to do so, of the Cattle Utilization Cooperative of e.g., by integrating artificial intelligence Hungarian landowners Karoly Ereky and implementing machine learning in published his book „Biotechnologie der the instruments they are developing and Fleisch-, Fett- und Milcherzeugung im PROF. bringing to the market. landwirtschaftlichen Grossbetriebe“ in HORST DOMDEY Berlin. Hence, 2019 is the year in which CEO of BioM; Spokesman Bavarian Last but not least, we are witnessing we can celebrate the 100th anniversary Biotechnology Cluster how the shift from experimentally of the term biotechnology. based inventions and innovations to the creation of new diagnostic concepts and Today, modern biotechnology provides treatments based on the use of big data a strong impetus for the economy, the research landscape is – albeit slowly – taking off. With the help of DigiMed and, above all, the health care sector. In Germany, we have Bayern, a EUR 22.5 million program funded by the State produced a respectable number of very successful biotech of Bavaria, we have taken the lead in Germany in this companies, such as Qiagen, Evotec,